secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0000950170-24-003514
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix publishes real-world data showing KidneyIntelX slows CKD progression and improves diabetes control
--------------------------------------------------------------------------------

- Study of 2,569 patients with Type 2 diabetes and DKD: KidneyIntelX deployment associated with slowed kidney function decline and improved A1C levels.
- 61% increase in preventative drug prescriptions among high-risk group; improved specialist referrals.
- KidneyIntelX has Medicare, Medicaid, and Blue Cross coverage; FDA de novo authorization received June 2023.
- 27% of study cohort were Black patients; median age 68, BMI 30, 89% hypertension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024003514/0000950170-24-003514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024003514/rnlx-20240110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer